Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.38 +7.6% TUNG 1.72 +1.8% LGO 1.01 −2.4% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.30 −2.0% SGZ 0.045 +0.0% S 0.135 +12.5% GRSL 0.310 −3.1% DEX 0.390 +1.3% WMS 0.040 +0.0% EMPR 0.840 +2.4% SAGA 0.480 +0.0% ABX 51.73 −0.9% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.38 +7.6% TUNG 1.72 +1.8% LGO 1.01 −2.4% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.30 −2.0% SGZ 0.045 +0.0% S 0.135 +12.5% GRSL 0.310 −3.1% DEX 0.390 +1.3% WMS 0.040 +0.0% EMPR 0.840 +2.4% SAGA 0.480 +0.0% ABX 51.73 −0.9%
Other Admin

Neurothera Labs Announces Adoption of Semi-Annual Reporting

By The Northwire Desk — AI Analysis May 20, 2026 · 17:00 NTLX · 0.155 NeuroThera Labs Inc.
NTLX · Price

Executive Summary

  • Neurothera Labs Inc. has adopted a semi-annual financial reporting ("SAR") framework, moving from quarterly to semi-annual filings.
  • The transition is being conducted under the Coordinated Blanket Order 5LT-933 to reduce administrative and financial burdens.
  • The company will no longer file interim reports or MD&A for the first and third quarters of the fiscal year.

Key Details

  • Reporting Schedule Changes:
    • No interim report or MD&A will be filed for Q1 (ending March 31, 2026).
    • No interim report or MD&A will be filed for Q3 (ending September 30, 2026).
  • Ongoing Reporting Obligations:
    • Audited annual consolidated financial statements must be filed within 120 days of December 31.
    • Six-month interim financial reports must be filed within 60 days of June 30.
  • Eligibility Criteria: The company meets the pilot program requirements, including annual revenues of less than $10 million and a clean 12-month continuous disclosure record.
Read the original news release →

More from NeuroThera Labs Inc.

Jun 30, 2026 · 18:00

Pre-revenue neurology and cannabis-tech company raises capital at a discount to fund operations and settle parent company debt.

Financings Jun 03, 2026 · 17:15

Neurothera Closes Cashless Quantum-Tech Acquisition, But Dilution and Clinical Stage Risks Keep Upside Capped

M&A / Property May 27, 2026 · 08:00

Neurothera Labs Confirms Acquisition Closing Amidst Significant Equity Dilution and Regulatory Scrutiny

M&A / Property Apr 30, 2026 · 10:59

Neurothera Labs Announces Continuance into Ontario

Other Apr 23, 2026 · 18:00

Neurothera Labs Engages bullVestor for Investor Relations Activities

Other Mar 16, 2026 · 07:31

NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy

M&A / Property